Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy (PEMVITASTART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02679443
Recruitment Status : Completed
First Posted : February 10, 2016
Last Update Posted : April 25, 2017
Sponsor:
Information provided by (Responsible Party):
Dr. Navneet Singh, Postgraduate Institute of Medical Education and Research

Brief Summary:

Folic acid (FA; folate) in the dose of 350-1,000 μg daily should be supplemented, daily, starting 7 days before the first dose of pemetrexed based chemotherapy and should be continued while the patient is on therapy and for 21 days after cessation of therapy. Vitamin B12 injections (1,000 μg i.m.) should also be started 1 week before the first dose of chemotherapy. However, the evidence for delaying chemotherapy by seven days for the purpose of giving vitamin B12 and FA supplementation is not robust. Observational and prospective single arm studies have not shown any increased toxicity if pemetrexed was started earlier than the recommended duration of supplementation. In a resource constrained setting, this will lead to one additional visit and 1-week chemotherapy delay which may be inconvenient for patients.

Hence an open label, randomized control trial is being undertaken to evaluate if there are any differences in pemetrexed related hematological toxicity amongst patients who receive delayed initiation of chemotherapy (following 5 - 7 days of vitamin B12 and FA supplementation; Delayed Arm) as compared to those in whom vitamin B12 and FA supplementation is starting simultaneously (within 24 hours) of initiation of chemotherapy (Immediate Arm).


Condition or disease Intervention/treatment Phase
Lung Adenocarcinoma Neutropenia Anemia Thrombocytopenia Nonsquamous Nonsmall Cell Neoplasm of Lung Dietary Supplement: Folate and B12 Not Applicable

Detailed Description:

Chemotherapy Regimen:

All patients will receive pemetrexed and cisplatin in doses of 500 mg and 65 mg, respectively, per square meter of body surface area each on day 1 of a 3-week cycle. Patients with contraindications to administration of cisplatin, those who are intolerant to cisplatin, or develop grade 3 or 4 adverse events from cisplatin will be given carboplatin in combination with pemetrexed. Carboplatin will be given at a dose calculated to produce an area under the concentration-time curve (AUC) of 5.0mg/mL/min. Dose modifications of either pemetrexed or the platinum agent or both will be done in case of significant change in PS or toxicity from or intolerance to dose administered in the previous cycle.

Supplementation:

  1. Folic acid (FA) supplementation will be given to all patients orally in the dose of 5 ml (1000 μg) once daily of VITCOFOL (FDC Limited, Mumbai, India) pediatric formulation, which contains 200 μg FA/ml of the preparation. Patients will be instructed to measure the prescribed dose using a 5 ml plastic syringe containing markings at every 0.5 ml. Patients will also be instructed not to take any additional multivitamin supplements. In addition to FA supplementation, all patients will also be started simultaneously on oral iron (ferrous sulphate 200 mg twice a day). Once initiated, both FA and ferrous sulphate will be given on a daily basis and continued throughout the duration of chemotherapy and for at least 3 weeks beyond the last cycle.
  2. Vitamin B12 supplementation will be given to all patients intramuscularly in the dose of 1000 μg along with each cycle of chemotherapy (maximum of six doses during the study period).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 161 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Optimum Duration of Vitamin B12 and Folate Supplementation in Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Undergoing Pemetrexed Containing Chemotherapy: a Randomized Controlled Trial
Actual Study Start Date : July 2015
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016


Arm Intervention/treatment
No Intervention: Delayed Arm
Participants are started on folate and vitamin B12 supplementation for 5-7 days prior to initiation of chemotherapy
Experimental: Immediate Arm
Participants are started on folate and vitamin B12 supplementation simultaneously with chemotherapy (within 24 hours of initiation of chemotherapy)
Dietary Supplement: Folate and B12
Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.




Primary Outcome Measures :
  1. Incidence of any grade hematological toxicity [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    Incidence of Grade 1-5 Anemia, Grade 1-5 Neutropenia, Grade 1-5 Thrombocytopenia (all graded according to NCI CTCAE Version 3.0) related to pemetrexed-platinum doublet chemotherapy during the study period


Secondary Outcome Measures :
  1. Incidence of grade 3/4 hematological toxicity [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    Incidence of Grade 3-4 Anemia, Grade 3-4 Neutropenia, Grade 3-4 Thrombocytopenia (all graded according to NCI CTCAE Version 3.0) related to pemetrexed-platinum doublet chemotherapy during the study period

  2. Number of doses of G-CSF administered [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    Number of doses of G-CSF (granulocyte colony stimulating factor) administered during the study period

  3. Number of doses of ESAs administered [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    Number of doses of ESAs (erythropoiesis stimulating agents) administered during the study period

  4. Number of PRBC transfusions administered [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    Number of PRBC (packed red blood cell) transfusions administered during the study period

  5. Relative Dose Intensity (RDI) delivered [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    RDI (in percentage) will be calculated as [(delivered dosage/predicted dosage)*100]. This will be calculated separately for pemetrexed and platinum compounds for each chemotherapy cycle and also averaged for the total duration of chemotherapy

  6. Number of Inter-Cycle Delays (ICDs) [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    ICD will be defined as a delay of at least 7 days between scheduled date and actual date of administration of a given cycle of chemotherapy


Other Outcome Measures:
  1. Changes in serum levels of folic acid and homocysteine [ Time Frame: Completion of six cycles (average of 18 weeks; each cycle is 21 days) of pemetrexed-platinum doublet chemotherapy ]
    After third and after sixth cycle of pemetrexed-platinum doublet chemotherapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Locally advanced or metastatic (Stage IIIB/IV) NSCLC and Stage III A NSCLC, not scheduled for upfront surgical resection
  • Nonsquamous histology (including adenocarcinoma)
  • At least one unidimensionally measurable lesion, according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.0), or at least one nonmeasurable lesion that was assessable using conventional techniques or a spiral computed tomography scan
  • An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • No previous chemotherapy for advanced disease and no previous targeted molecular therapy
  • Adequate liver and renal function;
  • Previous radiation therapy is permitted if completed >4 weeks before enrollment and the patient has recovered from any treatment-related toxicity.

Exclusion Criteria:

  • Hemoglobin value < 9gm/dl
  • Required erythropoiesis stimulating agents or blood transfusions in the recent past (4 months)
  • Symptomatic untreated brain metastasis
  • Any previous malignancy
  • Concurrent use of any other tumor therapy
  • Active infection or a serious concomitant disorder
  • Inability to interrupt nonsteroidal anti-inflammatory agents
  • Inability or unwillingness to take folic acid, vitamin B12, or dexamethasone supplementation
  • Pregnancy or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02679443


Locations
Layout table for location information
India
PGIMER
Chandigarh, India, 160012
Sponsors and Collaborators
Postgraduate Institute of Medical Education and Research
Investigators
Layout table for investigator information
Principal Investigator: Navneet Singh, MD DM PGIMER, Chandigarh
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Navneet Singh, Associate Professor, Postgraduate Institute of Medical Education and Research
ClinicalTrials.gov Identifier: NCT02679443    
Other Study ID Numbers: NK/2376/DM/913
First Posted: February 10, 2016    Key Record Dates
Last Update Posted: April 25, 2017
Last Verified: April 2017
Keywords provided by Dr. Navneet Singh, Postgraduate Institute of Medical Education and Research:
Lung Adenocarcinoma
Non-squamous NSCLC
Chemotherapy
Pemetrexed
Vitamin B12
Folate
Supplementation
Cytopenia
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Adenocarcinoma of Lung
Lung Neoplasms
Thrombocytopenia
Neutropenia
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Blood Platelet Disorders
Hematologic Diseases
Agranulocytosis
Leukopenia
Leukocyte Disorders
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases